Back to Search
Start Over
Supplementary Data from Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- Supplementary Data from Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....92db2a6e3d710b3ce86c0086e5b779bb
- Full Text :
- https://doi.org/10.1158/1078-0432.22486400